Profound Medical Corp. (NASDAQ: PROF) Stock Competitors & Peer Comparison
See PROF's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PROF and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PROF | $6.90 | +1.17% | 247.1M | -6.94 | -$0.98 | N/A |
| ABT | $108.99 | -1.34% | 188.2B | 20.88 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $94.38 | +2.39% | 119.2B | 16.84 | $5.53 | +3.08% |
| SYK | $304.31 | -2.52% | 118.1B | 23.00 | $13.39 | +1.13% |
| BSX | $48.01 | -0.74% | 69.8B | 15.15 | $3.10 | N/A |
| EW | $90.06 | -0.84% | 51.7B | 33.25 | $2.70 | N/A |
| DXCM | $88.04 | -1.84% | 33.9B | 35.18 | $2.55 | N/A |
| GEHC | $68.94 | -2.30% | 31.5B | 15.29 | $4.56 | +0.20% |
| PHG | $25.93 | -1.67% | 25.5B | 14.88 | $1.75 | +3.80% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
PROF vs ABT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ABT has a market cap of 188.2B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ABT trades at $108.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ABT's P/E ratio is 20.88. In terms of profitability, PROF's ROE is -0.56%, compared to ABT's ROE of +0.11%. Regarding short-term risk, PROF is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for PROF.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
PROF vs BSX-PA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PROF's ROE is -0.56%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PROF is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
PROF vs MDT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, MDT has a market cap of 119.2B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while MDT trades at $94.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas MDT's P/E ratio is 16.84. In terms of profitability, PROF's ROE is -0.56%, compared to MDT's ROE of +0.14%. Regarding short-term risk, PROF is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for PROF.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
PROF vs SYK Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SYK has a market cap of 118.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SYK trades at $304.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SYK's P/E ratio is 23.00. In terms of profitability, PROF's ROE is -0.56%, compared to SYK's ROE of +0.16%. Regarding short-term risk, PROF is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for PROF.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
PROF vs BSX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BSX has a market cap of 69.8B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BSX trades at $48.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BSX's P/E ratio is 15.15. In terms of profitability, PROF's ROE is -0.56%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PROF is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
PROF vs EW Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while EW trades at $90.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas EW's P/E ratio is 33.25. In terms of profitability, PROF's ROE is -0.56%, compared to EW's ROE of +0.10%. Regarding short-term risk, PROF is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for PROF.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
PROF vs DXCM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, DXCM has a market cap of 33.9B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while DXCM trades at $88.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas DXCM's P/E ratio is 35.18. In terms of profitability, PROF's ROE is -0.56%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, PROF is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for PROF.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
PROF vs GEHC Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, GEHC has a market cap of 31.5B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while GEHC trades at $68.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas GEHC's P/E ratio is 15.29. In terms of profitability, PROF's ROE is -0.56%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PROF is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for PROF.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
PROF vs PHG Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, PHG has a market cap of 25.5B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while PHG trades at $25.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas PHG's P/E ratio is 14.88. In terms of profitability, PROF's ROE is -0.56%, compared to PHG's ROE of +0.10%. Regarding short-term risk, PROF is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for PROF.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
PROF vs ZBH Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ZBH has a market cap of 19.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ZBH trades at $98.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ZBH's P/E ratio is 11.67. In terms of profitability, PROF's ROE is -0.56%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PROF is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for PROF.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
PROF vs ABMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PROF's ROE is -0.56%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PROF is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
PROF vs PEN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while PEN trades at $322.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas PEN's P/E ratio is 83.90. In terms of profitability, PROF's ROE is -0.56%, compared to PEN's ROE of +0.11%. Regarding short-term risk, PROF is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
PROF vs SWAV Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PROF's ROE is -0.56%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PROF is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
PROF vs SNN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SNN trades at $28.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SNN's P/E ratio is 13.50. In terms of profitability, PROF's ROE is -0.56%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PROF is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for PROF.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
PROF vs ALGN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ALGN trades at $158.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ALGN's P/E ratio is 14.57. In terms of profitability, PROF's ROE is -0.56%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, PROF is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for PROF.Check ALGN's competition here
Glaukos Corporation (NYSE: GKOS)
PROF vs GKOS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while GKOS trades at $178.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas GKOS's P/E ratio is -209.80. In terms of profitability, PROF's ROE is -0.56%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, PROF is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for PROF.Check GKOS's competition here
Globus Medical, Inc. (NYSE: GMED)
PROF vs GMED Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, GMED has a market cap of 10.5B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while GMED trades at $78.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas GMED's P/E ratio is 17.59. In terms of profitability, PROF's ROE is -0.56%, compared to GMED's ROE of +0.12%. Regarding short-term risk, PROF is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for PROF.Check GMED's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
PROF vs BIO Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BIO trades at $385.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BIO's P/E ratio is 41.79. In terms of profitability, PROF's ROE is -0.56%, compared to BIO's ROE of +0.03%. Regarding short-term risk, PROF is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
PROF vs BIO-B Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BIO-B trades at $381.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BIO-B's P/E ratio is -67.15. In terms of profitability, PROF's ROE is -0.56%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, PROF is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for PROF.Check BIO-B's competition here
Insulet Corp. (NASDAQ: PODD)
PROF vs PODD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, PODD has a market cap of 10.4B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while PODD trades at $146.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas PODD's P/E ratio is 25.65. In terms of profitability, PROF's ROE is -0.56%, compared to PODD's ROE of +0.27%. Regarding short-term risk, PROF is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for PROF.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
PROF vs MASI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas MASI's P/E ratio is 44.43. In terms of profitability, PROF's ROE is -0.56%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PROF is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for PROF.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
PROF vs BRKR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BRKR has a market cap of 9B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BRKR trades at $58.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BRKR's P/E ratio is 29.85. In terms of profitability, PROF's ROE is -0.56%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, PROF is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
PROF vs BRKRP Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BRKRP trades at $432.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BRKRP's P/E ratio is 238.04. In terms of profitability, PROF's ROE is -0.56%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, PROF is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BRKRP's competition here
Inari Medical, Inc. (NASDAQ: NARI)
PROF vs NARI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas NARI's P/E ratio is -59.24. In terms of profitability, PROF's ROE is -0.56%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PROF is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for PROF.Check NARI's competition here
Haemonetics Corporation (NYSE: HAE)
PROF vs HAE Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while HAE trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas HAE's P/E ratio is 20.52. In terms of profitability, PROF's ROE is -0.56%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PROF is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for PROF.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
PROF vs LIVN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while LIVN trades at $82.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas LIVN's P/E ratio is 19.29. In terms of profitability, PROF's ROE is -0.56%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, PROF is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for PROF.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
PROF vs ITGR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ITGR trades at $126.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ITGR's P/E ratio is 19.76. In terms of profitability, PROF's ROE is -0.56%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, PROF is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
PROF vs IRTC Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while IRTC trades at $122.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas IRTC's P/E ratio is -287.05. In terms of profitability, PROF's ROE is -0.56%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, PROF is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for PROF.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
PROF vs AXNX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PROF's ROE is -0.56%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PROF is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
PROF vs TMDX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while TMDX trades at $88.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas TMDX's P/E ratio is 44.15. In terms of profitability, PROF's ROE is -0.56%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, PROF is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for PROF.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
PROF vs NEOG Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while NEOG trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas NEOG's P/E ratio is 41.57. In terms of profitability, PROF's ROE is -0.56%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, PROF is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for PROF.Check NEOG's competition here
AxoGen, Inc. (NASDAQ: AXGN)
PROF vs AXGN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while AXGN trades at $48.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas AXGN's P/E ratio is 123.95. In terms of profitability, PROF's ROE is -0.56%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, PROF is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for PROF.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
PROF vs UFPT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while UFPT trades at $287.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas UFPT's P/E ratio is 29.27. In terms of profitability, PROF's ROE is -0.56%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PROF is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for PROF.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
PROF vs ESTA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ESTA trades at $74.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ESTA's P/E ratio is -57.38. In terms of profitability, PROF's ROE is -0.56%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, PROF is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for PROF.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
PROF vs NUVA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PROF's ROE is -0.56%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PROF is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for PROF.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
PROF vs NVCR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while NVCR trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas NVCR's P/E ratio is -13.57. In terms of profitability, PROF's ROE is -0.56%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, PROF is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for PROF.Check NVCR's competition here
Butterfly Network, Inc. (NYSE: BFLY)
PROF vs BFLY Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BFLY trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BFLY's P/E ratio is -30.35. In terms of profitability, PROF's ROE is -0.56%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, PROF is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BFLY's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
PROF vs INSP Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while INSP trades at $63.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas INSP's P/E ratio is 27.34. In terms of profitability, PROF's ROE is -0.56%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PROF is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for PROF.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
PROF vs CNMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while CNMD trades at $49.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas CNMD's P/E ratio is 10.84. In terms of profitability, PROF's ROE is -0.56%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, PROF is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
PROF vs ATEC Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ATEC trades at $9.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ATEC's P/E ratio is -155.50. In terms of profitability, PROF's ROE is -0.56%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, PROF is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for PROF.Check ATEC's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
PROF vs TNDM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while TNDM trades at $20.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas TNDM's P/E ratio is -21.97. In terms of profitability, PROF's ROE is -0.56%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, PROF is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for PROF.Check TNDM's competition here
Heska Corporation (NASDAQ: HSKA)
PROF vs HSKA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PROF's ROE is -0.56%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PROF is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for PROF.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
PROF vs IART Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while IART trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas IART's P/E ratio is 6.97. In terms of profitability, PROF's ROE is -0.56%, compared to IART's ROE of -0.01%. Regarding short-term risk, PROF is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for PROF.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
PROF vs AORT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while AORT trades at $25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas AORT's P/E ratio is 42.67. In terms of profitability, PROF's ROE is -0.56%, compared to AORT's ROE of -0.01%. Regarding short-term risk, PROF is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for PROF.Check AORT's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
PROF vs PRCT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while PRCT trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas PRCT's P/E ratio is -11.02. In terms of profitability, PROF's ROE is -0.56%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, PROF is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for PROF.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
PROF vs AVNS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas AVNS's P/E ratio is 27.77. In terms of profitability, PROF's ROE is -0.56%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PROF is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for PROF.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
PROF vs LMRI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while LMRI trades at $12.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas LMRI's P/E ratio is -23.15. In terms of profitability, PROF's ROE is -0.56%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, PROF is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for PROF.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
PROF vs SILK Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SILK's P/E ratio is -18.96. In terms of profitability, PROF's ROE is -0.56%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PROF is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SILK's competition here
Enovis Corporation (NYSE: ENOV)
PROF vs ENOV Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ENOV trades at $18.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ENOV's P/E ratio is 5.55. In terms of profitability, PROF's ROE is -0.56%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, PROF is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for PROF.Check ENOV's competition here
IRadimed Corporation (NASDAQ: IRMD)
PROF vs IRMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while IRMD trades at $84.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas IRMD's P/E ratio is 43.51. In terms of profitability, PROF's ROE is -0.56%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PROF is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for PROF.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
PROF vs FNA Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas FNA's P/E ratio is -19.83. In terms of profitability, PROF's ROE is -0.56%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PROF is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for PROF.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
PROF vs BVS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BVS has a market cap of 972.9M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BVS trades at $14.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BVS's P/E ratio is 18.89. In terms of profitability, PROF's ROE is -0.56%, compared to BVS's ROE of +0.28%. Regarding short-term risk, PROF is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
PROF vs CBLL Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, CBLL has a market cap of 932.3M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while CBLL trades at $24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas CBLL's P/E ratio is -13.96. In terms of profitability, PROF's ROE is -0.56%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, PROF is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
PROF vs BBNX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BBNX has a market cap of 896.2M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BBNX trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BBNX's P/E ratio is -12.07. In terms of profitability, PROF's ROE is -0.56%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, PROF is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BBNX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
PROF vs AHCO Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, AHCO has a market cap of 873.5M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while AHCO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas AHCO's P/E ratio is 13.10. In terms of profitability, PROF's ROE is -0.56%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, PROF is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for PROF.Check AHCO's competition here
InMode Ltd. (NASDAQ: INMD)
PROF vs INMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, INMD has a market cap of 853M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while INMD trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas INMD's P/E ratio is 10.31. In terms of profitability, PROF's ROE is -0.56%, compared to INMD's ROE of +0.12%. Regarding short-term risk, PROF is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for PROF.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
PROF vs AVR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, AVR has a market cap of 847.9M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while AVR trades at $9.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas AVR's P/E ratio is -4.49. In terms of profitability, PROF's ROE is -0.56%, compared to AVR's ROE of -0.78%. Regarding short-term risk, PROF is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for PROF.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
PROF vs CSII Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas CSII's P/E ratio is -20.83. In terms of profitability, PROF's ROE is -0.56%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PROF is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for PROF.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
PROF vs SIBN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SIBN has a market cap of 826.7M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SIBN trades at $18.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SIBN's P/E ratio is -54.82. In terms of profitability, PROF's ROE is -0.56%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, PROF is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for PROF.Check SIBN's competition here
Varex Imaging Corporation (NASDAQ: VREX)
PROF vs VREX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, VREX has a market cap of 779.7M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while VREX trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas VREX's P/E ratio is 19.49. In terms of profitability, PROF's ROE is -0.56%, compared to VREX's ROE of +0.05%. Regarding short-term risk, PROF is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
PROF vs SSII Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SSII has a market cap of 678.4M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SSII trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SSII's P/E ratio is -66.12. In terms of profitability, PROF's ROE is -0.56%, compared to SSII's ROE of -0.27%. Regarding short-term risk, PROF is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for PROF.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
PROF vs SRDX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PROF's ROE is -0.56%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, PROF is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
PROF vs CTKB Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, CTKB has a market cap of 607M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while CTKB trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas CTKB's P/E ratio is -24.90. In terms of profitability, PROF's ROE is -0.56%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, PROF is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CTKB's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
PROF vs KIDS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, KIDS has a market cap of 580.2M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while KIDS trades at $22.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas KIDS's P/E ratio is -19.14. In terms of profitability, PROF's ROE is -0.56%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PROF is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for PROF.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
PROF vs APEN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas APEN's P/E ratio is -9.43. In terms of profitability, PROF's ROE is -0.56%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PROF is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for PROF.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
PROF vs DCTH Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, DCTH has a market cap of 568.9M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while DCTH trades at $16.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas DCTH's P/E ratio is 1648.00. In terms of profitability, PROF's ROE is -0.56%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, PROF is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for PROF.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
PROF vs ZIMV Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PROF's ROE is -0.56%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, PROF is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
PROF vs CERS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, CERS has a market cap of 517.9M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while CERS trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas CERS's P/E ratio is -51.30. In terms of profitability, PROF's ROE is -0.56%, compared to CERS's ROE of -0.10%. Regarding short-term risk, PROF is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
PROF vs NPCE Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, NPCE has a market cap of 502.9M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while NPCE trades at $14.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas NPCE's P/E ratio is -25.88. In terms of profitability, PROF's ROE is -0.56%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, PROF is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for PROF.Check NPCE's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
PROF vs TCMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, TCMD has a market cap of 496.5M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while TCMD trades at $21.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas TCMD's P/E ratio is 20.38. In terms of profitability, PROF's ROE is -0.56%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, PROF is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for PROF.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
PROF vs SGHT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SGHT has a market cap of 456M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SGHT trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SGHT's P/E ratio is -14.96. In terms of profitability, PROF's ROE is -0.56%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, PROF is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for PROF.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
PROF vs CARL Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, CARL has a market cap of 421.9M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while CARL trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas CARL's P/E ratio is -10.85. In terms of profitability, PROF's ROE is -0.56%, compared to CARL's ROE of -0.38%. Regarding short-term risk, PROF is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CARL's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PROF vs CLPT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, CLPT has a market cap of 421.4M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while CLPT trades at $14.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas CLPT's P/E ratio is -11.91. In terms of profitability, PROF's ROE is -0.56%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, PROF is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
PROF vs SENS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SENS has a market cap of 413.8M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SENS trades at $9.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SENS's P/E ratio is -4.44. In terms of profitability, PROF's ROE is -0.56%, compared to SENS's ROE of -1.66%. Regarding short-term risk, PROF is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for PROF.Check SENS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
PROF vs PACB Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, PACB has a market cap of 403.8M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while PACB trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas PACB's P/E ratio is -3.17. In terms of profitability, PROF's ROE is -0.56%, compared to PACB's ROE of -49.62%. Regarding short-term risk, PROF is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for PROF.Check PACB's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
PROF vs OFIX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, OFIX has a market cap of 376.3M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while OFIX trades at $9.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas OFIX's P/E ratio is -6.06. In terms of profitability, PROF's ROE is -0.56%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, PROF is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for PROF.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
PROF vs CATX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, CATX has a market cap of 354.7M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while CATX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas CATX's P/E ratio is -2.34. In terms of profitability, PROF's ROE is -0.56%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PROF is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CATX's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
PROF vs TMCI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, TMCI has a market cap of 316.6M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while TMCI trades at $4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas TMCI's P/E ratio is -5.19. In terms of profitability, PROF's ROE is -0.56%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, PROF is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for PROF.Check TMCI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
PROF vs SMLR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PROF's ROE is -0.56%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, PROF is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for PROF.Check SMLR's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
PROF vs TLSI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, TLSI has a market cap of 306.6M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while TLSI trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas TLSI's P/E ratio is -2.96. In terms of profitability, PROF's ROE is -0.56%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, PROF is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for PROF.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
PROF vs CV Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, CV has a market cap of 298.3M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while CV trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas CV's P/E ratio is -2.39. In terms of profitability, PROF's ROE is -0.56%, compared to CV's ROE of -1.78%. Regarding short-term risk, PROF is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for PROF.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
PROF vs RCEL Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, RCEL has a market cap of 271.8M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while RCEL trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas RCEL's P/E ratio is -7.60. In terms of profitability, PROF's ROE is -0.56%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, PROF is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for PROF.Check RCEL's competition here
RxSight, Inc. (NASDAQ: RXST)
PROF vs RXST Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, RXST has a market cap of 270.7M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while RXST trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas RXST's P/E ratio is -5.79. In terms of profitability, PROF's ROE is -0.56%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PROF is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for PROF.Check RXST's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
PROF vs INFU Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, INFU has a market cap of 245.4M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while INFU trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas INFU's P/E ratio is 29.66. In terms of profitability, PROF's ROE is -0.56%, compared to INFU's ROE of +0.15%. Regarding short-term risk, PROF is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for PROF.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
PROF vs MGRM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas MGRM's P/E ratio is -12.00. In terms of profitability, PROF's ROE is -0.56%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, PROF is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for PROF.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
PROF vs ELMD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ELMD has a market cap of 228.4M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ELMD trades at $27.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ELMD's P/E ratio is 21.06. In terms of profitability, PROF's ROE is -0.56%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, PROF is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for PROF.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
PROF vs NVRO Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PROF's ROE is -0.56%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PROF is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for PROF.Check NVRO's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
PROF vs BSGM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PROF's ROE is -0.56%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, PROF is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for PROF.Check BSGM's competition here
Neuronetics, Inc. (NASDAQ: STIM)
PROF vs STIM Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, STIM has a market cap of 189.3M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while STIM trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas STIM's P/E ratio is -6.18. In terms of profitability, PROF's ROE is -0.56%, compared to STIM's ROE of -1.51%. Regarding short-term risk, PROF is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for PROF.Check STIM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
PROF vs LUCD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, LUCD has a market cap of 181.5M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while LUCD trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas LUCD's P/E ratio is -2.57. In terms of profitability, PROF's ROE is -0.56%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PROF is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for PROF.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
PROF vs MDGS Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PROF's ROE is -0.56%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PROF is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for PROF.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
PROF vs QIPT Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PROF's ROE is -0.56%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PROF is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for PROF.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
PROF vs FOCL Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, FOCL has a market cap of 156.3M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while FOCL trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas FOCL's P/E ratio is -4.03. In terms of profitability, PROF's ROE is -0.56%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, PROF is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for PROF.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
PROF vs QSI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, QSI has a market cap of 153.1M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while QSI trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas QSI's P/E ratio is -1.68. In terms of profitability, PROF's ROE is -0.56%, compared to QSI's ROE of -0.47%. Regarding short-term risk, PROF is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for PROF.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
PROF vs INGN Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, INGN has a market cap of 147.6M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while INGN trades at $5.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas INGN's P/E ratio is -5.99. In terms of profitability, PROF's ROE is -0.56%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PROF is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for PROF.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
PROF vs QTRX Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, QTRX has a market cap of 121.5M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while QTRX trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas QTRX's P/E ratio is -1.02. In terms of profitability, PROF's ROE is -0.56%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, PROF is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for PROF.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
PROF vs ICAD Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PROF's ROE is -0.56%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, PROF is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for PROF.Check ICAD's competition here
LENSAR Inc (NASDAQ: LNSR)
PROF vs LNSR Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, LNSR has a market cap of 101.3M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while LNSR trades at $8.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas LNSR's P/E ratio is 8.42. In terms of profitability, PROF's ROE is -0.56%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, PROF is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for PROF.Check LNSR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
PROF vs HJLI Comparison September 2026
Profound Medical Corp. (NASDAQ: PROF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROF stands at 247.1M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PROF is priced at $6.90 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROF currently has a P/E ratio of -6.94, whereas HJLI's P/E ratio is N/A. In terms of profitability, PROF's ROE is -0.56%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, PROF is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for PROF.Check HJLI's competition here